Dendritic cells: Indispensable?

Cancer Journal

Volumn 17, Issue 5, 2011, Pages 337-342

  Schuler, Gerold ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

adjuvant; cancer immunotherapy; cancer vaccine; Dendritic cell; mutated antigens

Indexed keywords

CANCER VACCINE; MELANOMA ANTIGEN 3; PROVENGE; VACCINE;

CANCER IMMUNIZATION; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL FUNCTION; CELL MATURATION; DENDRITIC CELL; DRUG DESIGN; HUMAN; IMMUNE SYSTEM; IMMUNIZATION; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; STEADY STATE; T LYMPHOCYTE;

CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; DRUG DESIGN; HUMANS; T-LYMPHOCYTES; VACCINATION; VACCINES;

EID: 80053346852     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e3182350077     Document Type: Review

References (81)

1. Steinman RM, Idoyaga J. Features of the dendritic cell lineage. Immunol Rev. 2010;234:5-17.
2. Steinman RM. Dendritic cells: understanding immunogenicity. Eur J Immunol. 2007;37(suppl 1):S53-S60. (Pubitemid 350131268)
3. Steinman RM. Dendritic cells in vivo: a key target for a new vaccine science. Immunity. 2008;29:319-324.
4. Liu K, Nussenzweig MC. Origin and development of dendritic cells. Immunol Rev. 2010;234:45-54.
5. Ueno H, Klechevsky E, Schmitt N, et al. Targeting human dendritic cell subsets for improved vaccines. Semin Immunol. 2011;23:21-27.
6. Liu K, Victora GD, Schwickert TA, et al. In vivo analysis of dendritic cell development and homeostasis. Science. 2009;324:392-397.
7. Cheong C, Matos I, Choi JH, et al. Microbial stimulation fully differentiates monocytes to DC-SIGN/CD209(+) dendritic cells for immune T cell areas. Cell. 2010;143:416-429.
8. Huang Q, Liu D, Majewski P, et al. The plasticity of dendritic cell responses to pathogens and their components. Science. 2001;294:870-875. (Pubitemid 33032108)
9. Melief CJ. Cancer immunotherapy by dendritic cells. Immunity. 2008;29: 372-383.
10. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol. 2007;25: 267-296. (Pubitemid 46697910)
11. Villablanca EJ, Raccosta L, Zhou D, et al. Tumor-mediated liver X receptor-alpha activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses. Nat Med. 2010;16: 98-105.
12. Kukreja A, Radfar S, Sun BH, et al. Dominant role of CD47- thrombospondin-1 interactions in myeloma-induced fusion of human dendritic cells: implications for bone disease. Blood. 2009;114:3413-3421.
13. Aspord C, Pedroza-Gonzalez A, Gallegos M, et al. Breast cancer instructs dendritic cells to prime interleukin 13Ysecreting CD4+ T cells that facilitate tumor development. J Exp Med. 2007;204:1037-1047. (Pubitemid 46798148)
14. Speiser DE, Romero P. Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity. Semin Immunol. 2010;22: 144-154.
15. Schwartzentruber DJ, Lawson DH, Richards JM, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011;364:2119-2127.
16. Speiser DE, Lienard D, Rufer N, et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest. 2005;115:739-746. (Pubitemid 40322250)
17. Bioley G, Jandus C, Tuyaerts S, et al. Melan-A/MART-1Yspecific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers. J Immunol. 2006;177:6769-6779. (Pubitemid 44715041)
18. Brichard VG, Lejeune D. GSKs antigen-specific cancer immunotherapy programme: pilot results leading to phase III clinical development. Vaccine. 2007;25(suppl 2):B61-B71. (Pubitemid 47488551)
19. Atanackovic D, Altorki NK, Cao Y, et al. Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc Natl Acad Sci U S A. 2008;105:1650-1655. (Pubitemid 351346569)
20. Melief CJ, van der Burg SH. Immunotherapy of established (pre)- malignant disease by synthetic long peptide vaccines. Nat Rev Cancer. 2008;8:351-360. (Pubitemid 351589701)
21. Faure F, Mantegazza A, Sadaka C, et al. Long-lasting cross-presentation of tumor antigen in human DC. Eur J Immunol. 2009;39:380-390.
22. Kenter GG,Welters MJ, Valentijn AR, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med. 2009; 361:1838-1847.
23. Vergati M, Intrivici C, Huen NY, et al. Strategies for cancer vaccine development. J Biomed Biotechnol. 2010;2010:596432.
24. Rittig SM, Haentschel M, Weimer KJ, et al. Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. Mol Ther. 2011;19: 990-999.
25. Bonifaz LC, Bonnyay DP, Charalambous A, et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med. 2004;199:815-824. (Pubitemid 38375201)
26. Hawiger D, Inaba K, Dorsett Y, et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med. 2001;194:769-779. (Pubitemid 32983013)
27. Dudziak D, Kamphorst AO, Heidkamp GF, et al. Differential antigen processing by dendritic cell subsets in vivo. Science. 2007;315:107-111. (Pubitemid 46196991)
28. Soares H, Waechter H, Glaichenhaus N, et al. A subset of dendritic cells induces CD4+ T cells to produce IFN-gamma by an IL-12-independent but CD70-dependent mechanism in vivo. J Exp Med. 2007;204:1095-1106. (Pubitemid 46798153)
29. Tacken PJ, Figdor CG. Targeted antigen delivery and activation of dendritic cells in vivo: steps towards cost effective vaccines. Semin Immunol. 2011;23:12-20.
30. Heit A, Schmitz F, OKeeffe M, et al. Protective CD8 T cell immunity triggered by CpG-protein conjugates competes with the efficacy of live vaccines. J Immunol. 2005;174:4373-4380. (Pubitemid 40396020)
31. Longhi MP, Trumpfheller C, Idoyaga J, et al. Dendritic cells require a systemic type I interferon response to mature and induce CD4+ TH1 immunity with poly IC as adjuvant. J Exp Med. 2009;206:1589-1602.
32. Cheong C, Choi JH, Vitale L, et al. Improved cellular and humoral immune responses in vivo following targeting of HIV Gag to dendritic cells within human anti-human DEC205 monoclonal antibody. Blood. 2010;116:3828-3838.
33. Flynn BJ, Kastenmuller K, Wille-Reece U, et al. Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates. Proc Natl Acad Sci U S A. 2011;108:7131-7136.
34. Gaucher D, Therrien R, Kettaf N, et al. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med. 2008;205:3119-3131.
35. Trautmann L, Sekaly RP. Solving vaccine mysteries: a systems biology perspective. Nat Immunol. 2011;12:729-731.
36. Okada H, Kalinski P, Ueda R, et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol. 2011;29:330-336.
37. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med. 1996;2:52-58. (Pubitemid 26028073)
38. Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009;115:3670-3679.
39. Kampgen E, Koch F, Heufler C, et al. Understanding the dendritic cell lineage through a study of cytokine receptors. J Exp Med. 1994;179: 1767-1776. (Pubitemid 24155658)
40. Sheikh NA, Jones LA. CD54 is a surrogate marker of antigen presenting cell activation. Cancer Immunol Immunother. 2008;57:1381-1390.
41. Eubel J, Enk AH. Dendritic cell vaccination as a treatment modality for melanoma. Expert Rev Anticancer Ther. 2009;9:1631-1642.
42. Engell-Noerregaard L, Hansen TH, Andersen MH, et al. Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother. 2009;58:1-14.
43. Lehrfeld TJ, Lee DI. Dendritic cell vaccines for the treatment of prostate cancer. Urol Oncol. 2008;26:576-580.
44. Fay JW, Palucka AK, Paczesny S, et al. Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells. Cancer Immunol Immunother. 2006;55:1209-1218. (Pubitemid 43992047)
45. Palucka AK, Ueno H, Connolly J, et al. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. J Immunother. 2006;29:545-557. (Pubitemid 44395279)
46. ORourke MG, Johnson M, Lanagan C, et al. Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol Immunother. 2003;52:387-395. (Pubitemid 36693759)
47. ORourke MG, Johnson MK, Lanagan CM, et al. Dendritic cell immunotherapy for stage IV melanoma. Melanoma Res. 2007;17:316-322. (Pubitemid 47462224)
48. de Vries IJ, Bernsen MR, Lesterhuis WJ, et al. Immunomonitoring tumorspecific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol. 2005;23:5779-5787.
49. Godelaine D, Carrasco J, Lucas S, et al. Polyclonal CTL responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.A1 peptide. J Immunol. 2003;171:4893-4897. (Pubitemid 37310612)
50. Schuler-Thurner B, Schultz ES, Berger TG, et al. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocytederived dendritic cells. J Exp Med. 2002;195:1279-1288. (Pubitemid 34564330)
51. Thurner B, Haendle I, Roder C, et al. Vaccination with mage-3A1 peptidepulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med. 1999;190:1669-1678. (Pubitemid 30002348)
52. Gajewski TF, Louahed J, Brichard VG. Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy. Cancer J. 2010;16:399-403.
53. Schadendorf D, Ugurel S, Schuler-Thurner B, et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol. 2006;17:563-570.
54. de Vries IJ, Lesterhuis WJ, Scharenborg NM, et al. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res. 2003;9:5091-5100. (Pubitemid 37413557)
55. Fong L, Brockstedt D, Benike C, et al. Dendritic cells injected via different routes induce immunity in cancer patients. J Immunol. 2001;166: 4254-4259. (Pubitemid 32224961)
56. Jonuleit H, Giesecke-Tuettenberg A, Tuting T, et al. A comparison of two types of dendritic cell as adjuvants for the induction of melanomaspecific T-cell responses in humans following intranodal injection. Int J Cancer. 2001;93:243-251. (Pubitemid 32574281)
57. Dubsky P, Saito H, Leogier M, et al. IL-15Yinduced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL. Eur J Immunol. 2007;37:1678-1690. (Pubitemid 46939501)
58. Anguille S, Smits EL, Cools N, et al. Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties. J Transl Med. 2009;7:109.
59. Romano E, Rossi M, Ratzinger G, et al. Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo. Clin Cancer Res. 2011;17:1984-1997.
60. Mailliard RB, Wankowicz-Kalinska A, Cai Q, et al. alpha-Type-1 polarized dendritic cells: a novel immunization tool with optimized CTLinducing activity. Cancer Res. 2004;64:5934-5937. (Pubitemid 39129387)
61. Boullart AC, Aarntzen EH, Verdijk P, et al. Maturation of monocytederived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration. Cancer Immunol Immunother. 2008;57:1589-1597.
62. Zobywalski A, Javorovic M, Frankenberger B, et al. Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70. J Transl Med. 2007;5:18.
63. Bozzacco L, Trumpfheller C, Siegal FP, et al. DEC-205 receptor on dendritic cells mediates presentation of HIV Gag protein to CD8+ T cells in a spectrum of human MHC I haplotypes. Proc Natl Acad Sci U S A. 2007;104:1289-1294. (Pubitemid 46183997)
64. Birkholz K, Schwenkert M, Kellner C, et al. Targeting of DEC-205 on human dendritic cells results in efficient MHC class-restricted antigen presentation. Blood. 2010;116:2277-2285.
65. Van Tendeloo VF, Ponsaerts P, Lardon F, et al. Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood. 2001;98:49-56.
66. Schaft N, Dorrie J, Thumann P, et al. Generation of an optimized polyvalent monocyte-derived dendritic cell vaccine by transfecting defined RNAs after rather than before maturation. J Immunol. 2005;174: 3087-3097. (Pubitemid 40279731)
67. Van Tendeloo VF, Van de Velde A, Van DA, et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci U S A. 2010;107:13824-13829.
68. Wilgenhof S, Van Nuffel AM, Corthals J, et al. Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma. J Immunother. 2011;34:448-456.
69. Gilboa E, Vieweg J. Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev. 2004;199:251-263. (Pubitemid 38744521)
70. Dorrie J, Schaft N, Muller I, et al. Introduction of functional chimeric E/L-selectin by RNA electroporation to target dendritic cells from blood to lymph nodes. Cancer Immunol Immunother. 2008;57:467-477. (Pubitemid 351170531)
71. Van Nuffel AM, Corthals J, Neyns B, et al. Immunotherapy of cancer with dendritic cells loaded with tumor antigens and activated through mRNA electroporation. Methods Mol Biol. 2010;629:405-452.
72. Calderhead DM, DeBenedette MA, Ketteringham H, et al. Cytokine maturation followed by CD40L mRNA electroporation results in a clinically relevant dendritic cell product capable of inducing a potent proinflammatory CTL response. J Immunother. 2008;31:731-741.
73. DeBenedette MA, Calderhead DM, Ketteringham H, et al. Priming of a novel subset of CD28+ rapidly expanding high-avidity effector memory CTL by post maturation electroporation-CD40L dendritic cells is IL-12 dependent. J Immunol. 2008;181:5296-5305.
74. Ueno H, Schmitt N, Klechevsky E, et al. Harnessing human dendritic cell subsets for medicine. Immunol Rev. 2010;234:199-212.
75. Ferlazzo G, Tsang ML, Moretta L, et al. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med. 2002;195:343-351. (Pubitemid 34461492)
76. Munz C, Dao T, Ferlazzo G, et al. Mature myeloid dendritic cell subsets have distinct roles for activation and viability of circulating human natural killer cells. Blood. 2005;105:266-273. (Pubitemid 40053092)
77. Terme M, Ullrich E, Delahaye NF, et al. Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat Immunol. 2008;9:486-494. (Pubitemid 351560517)
78. Chang DH, Osman K, Connolly J, et al. Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosylceramide loaded mature dendritic cells in cancer patients. J Exp Med. 2005;201:1503-1517. (Pubitemid 40664093)
79. Dranoff G. Coordinated tumor immunity. J Clin Invest. 2003;111: 1116-1118. (Pubitemid 36519926)
80. Zitvogel L,KeppO, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol. 2011;8:151-160.
81. Lesterhuis WJ, Punt CJ, Hato SV, et al. Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J Clin Invest. 2011;121:3100-3108.